BioCryst Pharmaceuticals (BCRX) Q3 2024 Earnings
BCRX·Reported November 4, 2024·Before market open
BioCryst Pharmaceuticals reported Q3 2024 revenue of $117.1M, missed analyst consensus of $127.7M by $10.6M. Diluted EPS came in at $-0.07.
Revenue
$117.1Mmissed by $10.6M
Consensus: $127.7MDiluted EPS
$-0.07met estimate
Consensus: $-0.07
Financial Snapshot
Trailing eight quarters through Q3 2024
Q3 2024 Earnings FAQ
Common questions about BioCryst Pharmaceuticals's Q3 2024 earnings report.
BioCryst Pharmaceuticals (BCRX) reported Q3 2024 earnings on November 4, 2024 before market open.
BioCryst Pharmaceuticals reported revenue of $117.1M and diluted EPS of $-0.07 for Q3 2024.
Revenue missed the consensus estimate of $127.7M by $10.6M. EPS beat the consensus estimate of $-0.07 by $0.00.
You can read the 10-Q periodic report (0001628280-24-045364) directly on SEC EDGAR. The filing index links above go to sec.gov.